Investigational drug · Phase 2
RBD1119
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Stable Coronary Artery Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "RBD1119"
First trial start
2026
Oct 16, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RBD1119", any sponsor or status.
Conditions studied
As listed on its trial records.
- Stable Coronary Artery Disease
Approved drugs for the same conditions: Coronary artery disease and heart attack
Largest trials
Live from ClinicalTrials.gov: studies naming "RBD1119" as an intervention, largest first.
- RBD1119 in Coronary Artery Disease (CAD)Pivotal-lookingNot yet recruiting
Ribocure Pharmaceuticals ABIndustry
NCT07884136 · 200 participants (planned) · Start Oct 16, 2026 · Primary completion Sep 30, 2027
Drug: RBD1119; Placebo · For: Stable Coronary Artery Disease
Sites: Gdynia, Poland; Grodzisk Mazowiecki, Poland; Krakow, Poland · 16 sites in all
- Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy ParticipantsActive, not recruiting
Suzhou Ribo Life Science Co. Ltd.Industry
NCT07042594 · 32 participants (planned) · Start Aug 26, 2025 · Primary completion Aug 5, 2026
Drug: RBD1119; Placebo · For: Healthy Volunteers
Sites: Adelaide, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.